Upacicalcet sodium hydrate clinical trials
Also written PLS240.
A product of Upacicalcet; its studies count on that page too.
How each study uses upacicalcet sodium hydrate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the upacicalcet sodium hydrate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PLS240
- 3
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Pathalys Pharma (3)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Upacicalcet
Studies
Open first, then newest update. How each study uses upacicalcet sodium hydrate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisNot yet recruitingPhase 3Pathalys PharmaNCT07890584Written as PLS240
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2CompletedPhase 3Pathalys PharmaNCT05836220Written as PLS240
- Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1CompletedPhase 3Pathalys PharmaNCT05832931Written as PLS240
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call upacicalcet sodium hydrate · ClinicalTrials.gg INT016332
- UNII (FDA) DH9LW5L96PUPACICALCET SODIUM HYDRATEOne source FDA
- NCI Thesaurus C151955Upacicalcet Sodium HydrateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DH9LW5L96P | UPACICALCET SODIUM HYDRATE | One source FDA |
| NCI Thesaurus | C151955 | Upacicalcet Sodium Hydrate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.